Your browser doesn't support javascript.
loading
New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors.
La Regina, Giuseppe; Bai, Ruoli; Coluccia, Antonio; Naccarato, Valentina; Famiglini, Valeria; Nalli, Marianna; Masci, Domiziana; Verrico, Annalisa; Rovella, Paola; Mazzoccoli, Carmela; Da Pozzo, Eleonora; Cavallini, Chiara; Martini, Claudia; Vultaggio, Stefania; Dondio, Giulio; Varasi, Mario; Mercurio, Ciro; Hamel, Ernest; Lavia, Patrizia; Silvestri, Romano.
Afiliação
  • La Regina G; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Roma, Italy.
  • Bai R; Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
  • Coluccia A; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Roma, Italy.
  • Naccarato V; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Roma, Italy.
  • Famiglini V; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Roma, Italy.
  • Nalli M; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Roma, Italy.
  • Masci D; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Roma, Italy.
  • Verrico A; Institute of Molecular Biology and Pathology (IBPM), CNR Consiglio Nazionale Delle Ricerche, C/o Sapienza University of Rome, Via Degli Apuli 4, I-00185 Roma, Italy.
  • Rovella P; Institute of Molecular Biology and Pathology (IBPM), CNR Consiglio Nazionale Delle Ricerche, C/o Sapienza University of Rome, Via Degli Apuli 4, I-00185 Roma, Italy.
  • Mazzoccoli C; Laboratorio di Ricerca Pre-Clinica e Traslazionale, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico Della Basilicata, Via Padre Pio 1, I-85028, Rionero in Vulture, Italy.
  • Da Pozzo E; Department of Pharmacy, University of Pisa, Via Bonanno Pisano 6, I-56126 Pisa, Italy.
  • Cavallini C; Department of Pharmacy, University of Pisa, Via Bonanno Pisano 6, I-56126 Pisa, Italy.
  • Martini C; Department of Pharmacy, University of Pisa, Via Bonanno Pisano 6, I-56126 Pisa, Italy.
  • Vultaggio S; Experimental Therapeutics IFOM-the FIRC Institute of Molecular Oncology Foundation, Via Adamello 16, 20139 Milan, Italy.
  • Dondio G; APHAD, Via Della Resistenza 65, 20090 Buccinasco MI, Italy.
  • Varasi M; Experimental Therapeutics IFOM-the FIRC Institute of Molecular Oncology Foundation, Via Adamello 16, 20139 Milan, Italy.
  • Mercurio C; Experimental Therapeutics IFOM-the FIRC Institute of Molecular Oncology Foundation, Via Adamello 16, 20139 Milan, Italy.
  • Hamel E; Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
  • Lavia P; Institute of Molecular Biology and Pathology (IBPM), CNR Consiglio Nazionale Delle Ricerche, C/o Sapienza University of Rome, Via Degli Apuli 4, I-00185 Roma, Italy.
  • Silvestri R; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Roma, Italy. Electronic address: romano.silvestri@uniroma1.it.
Eur J Med Chem ; 152: 283-297, 2018 May 25.
Article em En | MEDLINE | ID: mdl-29730191
ABSTRACT
We designed new 3-arylthio- and 3-aroyl-1H-indole derivatives 3-22 bearing a heterocyclic ring at position 5, 6 or 7 of the indole nucleus. The 6- and 7-heterocyclyl-1H-indoles showed potent inhibition of tubulin polymerization, binding of colchicine to tubulin and growth of MCF-7 cancer cells. Compounds 13 and 19 inhibited a panel of cancer cells and the NCI/ADR-RES multidrug resistant cell line at low nanomolar concentrations. Compound 13 at 50 nM induced 77% G2/M in HeLa cells, and at 20 nM caused 50% stable arrest of mitosis. As an inhibitor of HepG2 cells (IC50 = 20 nM), 13 was 4-fold superior to 19. Compound 13 was a potent inhibitor of the human U87MG glioblastoma cells at nanomolar concentrations, being nearly one order of magnitude superior to previously reported arylthioindoles. The present results highlight 13 as a robust scaffold for the design of new anticancer agents.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tubulina (Proteína) / Moduladores de Tubulina / Indóis / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tubulina (Proteína) / Moduladores de Tubulina / Indóis / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article